654-11-5

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Difluoro-4-methoxybenzaldehyde is used as a reagent for the synthesis of various pharmaceutical compounds. Its unique structure with fluorine substitutions and a methoxy group allows for the creation of new molecules with potential therapeutic applications.
Used in Chemical Synthesis:
3,5-Difluoro-4-methoxybenzaldehyde is used as a key intermediate in the synthesis of complex organic molecules. Its presence in the molecule can influence the reactivity and properties of the final product, making it a valuable component in the development of new chemical entities.
Used in Research and Development:
3,5-Difluoro-4-methoxybenzaldehyde is used as a research compound to study the effects of fluorine substitutions and methoxy groups on the chemical and physical properties of benzaldehyde derivatives. This can lead to a better understanding of the structure-activity relationships in various chemical systems and contribute to the discovery of new compounds with desired properties.

InChI:InChI=1/C8H6F2O2/c1-12-8-6(9)2-5(4-11)3-7(8)10/h2-4H,1H3

Upstream product

• 118276-06-5 3,5-difluoro-4-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 
• 123-11-5 4-methoxy-benzaldehyde 
• 28177-48-2 2,6-difluorophenol 
• 104197-15-1 3,5-difluoro-4-methoxybenzonitrile 

Downstream Products

• 124068-57-1 [1-(3,5-Difluoro-4-methoxy-phenyl)-meth-(E)-ylidene]-(2,2-dimethoxy-ethyl)-amine 
• 706786-41-6 (3,5-difluoro-4-methoxy-phenyl)-methanol 
• 101471-18-5 N-(3,5-difluoro-4-methoxybenzyl)-aminoacetaldehyde dimethyl acetal 
• 104197-16-2 1-(4'-methoxy-3',5'-difluorobenzyl)-1,3-dihydro-2H-imidazole-2-thione 
• 527750-92-1 (Z)-3-(3,5-difluoro-4-methoxyphenyl)-2-ethoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 527750-93-2 (Z)-3-(3,5-difluoro-4-methoxyphenyl)-2-propoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 527750-42-1 (E)-3-(3,5-difluoro-4-methoxyphenyl)-2-methyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 524945-14-0 (Z)-3-(3,5-difluoro-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1564086-99-2 C₁₄H₁₀ClF₂NOS 
• 1564088-70-5 2-(3,5-difluoro-4-hydroxyphenyl)-5-chlorobenzothiazole 
• 1564087-97-3 2-(3,5-difluoro-4-methoxyphenyl)-5-chlorobenzothiazole 

Relevant academic research and scientific papers

ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF

Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

Elemental fluorine. Part 21. (1) direct fluorination of benzaldehyde derivatives

Direct fluorination of a range of benzaldehyde derivatives gives mixtures of fluorobenzaldehyde and benzoyl fluoride products in ratios that depend upon the nature of the ring substituent Electron-withdrawing substituents give predominantly benzoyl fluoride derivatives, whereas electron-donating substituents lead to fluoroarene systems. Separation of ring-fluorinated products can be easily accomplished by esterification of the benzoyl fluoride side products. Scale-up of these processes to provide significant quantities of appropriate fluorobenzaldehyde systems has also been achieved using continuous flow techniques.

Elemental fluorine. Part 20. Direct fluorination of deactivated aromatic systems using microreactor techniques

Continuous flow microreactor technology has been used for the direct fluorination of a range of deactivated di- and tri-substituted aromatic systems.

Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4

The synthesis of a series of fluorinate d benzaldehydes and their use in the Wittig synthesis of fluoro-substituted stilbenes is described. 3,5-Difluoro-4-hydroxybenzaldehyde (6) and 3-fluoro-4-methoxybenzaldehyde (11) are prepared by Duff formylation of 3,5-difluorophenol and 2-fluoroanisole, respectively. 2-Methoxy-3,4-difluorobenzaldehyde was obtained by Friedel-Crafts formylation of 2,3-difluoroanisole with α,α-dichloromethyl methyl ether. The aldehydes were used to make a series of fluorinated analogues of the anticancer combretastatins A-1, A-2 and A-4. The in vitro anticancer properties of the fluoro combretastatins are reported. The most active fluoro analogue 3-deoxy-3-fluoro-combretastatin A-4 (Z-2) retains the potent cell growth inhibitory properties of CA-4.

A convenient route to new fluorinated photodynamic therapeutic photosensitizers based on meso-tetra(hydroxyphenyl)porphyrins

A general synthetic route was developed for the synthesis of new fluorinated tetra(hydroxyphenyl) porphyrins [5,10,15,20-tetrakis(2-fluoro-3-hydroxyphenyl)porphyrin 10, 5,10,15,20-tetrakis(2,4-difluoro-3-hydroxyphenyl)porphyrin 11, and 5,10,15,20-tetrakis(3,5-difluoro-4-hydroxyphenyl)porphyrin 12], analogues of sensitisers 1-3 which are known to be active in vivo in cancer photodynamic therapy.

DOPAMINE-BETA-HYDROXYLASE INHIBITORS

Potent DBH inhibitors having the formula can be used to inhibit DBH activity in mammals.

4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols

Compounds of formula (I) and pharmaceutically acceptable salts thereof are described in which, n is 0 to 5; X1 to X5 are any accessible combination of hydrogen, halogen, C1 6alkyl, C1 6alkoxy, cyano, nitro, SONH2, SO2NH2, SO2CH3, SO2CH2F, SO2CHF2, SO2CF3, CF3, CHO, OH, CH2OH, CO2H, or CO2CpH2p+1wherein p is 1 to 4; R1 is phenyl substituted by X1 to X5, C1 4alkyl, C3 6cycloalkyl, or an arylC1 4alkyl group substituted by X1 to X5; R2 is hydrogen, C1 4alkyl or (CH2)m-CO2R3; m is 0 to 5; and R3 is H or C1 4alkyl. These compounds are dopamine-β-hydroxylase inhibitors. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of these compounds are described.

Dopamine-β-hydroxylase inhibitors and use thereof

The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-β-hydroxylase inhibitors.